Interferon-free, direct-acting antiviral (DAA) drug combination therapy is now a standard of care for patients with chronic HCV infection. However, poor compliance with therapy and the existence of pretreatment antiviral drug resistance may compromise efficacy of such drug therapy. Naturally occurring (preexisting) or treatment-induced mutations in the viral genomic sequences that are targets of such antiviral agents can lead to antiviral resistance and therapeutic failure.
Certain FDA-approved DAA drugs for treating chronic HCV due to genotypes 1a, 1b, and 3 (regardless of subtypes) require pretreatment testing for resistance-associated substitutions in the relevant HCV genomic sequences to best guide selection of optimal DAA combination therapy.
Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
Supplies: Aliquot tube, 5 mL (T465)
Collection Container/Tube: Serum gel
Submission Container/Tube: Polypropylene vial (T465)
Specimen Volume: 2.5 mL
1. Centrifuge blood collection tube per collection tube manufacturer's instructions.
2. Pour off serum into aliquot tube.
Monday through Friday, 7 a.m.–11 p.m.